ANDREWS RONALD ASBURY 4

4 · PLUS THERAPEUTICS, INC. · Filed May 18, 2026

AI-generated summary of this filing

Updated May 18, 2026

Plus Therapeutics (PSTV) Director Ronald Asbury Andrews Receives 8,972 RSUs

What Happened

Ronald Asbury Andrews, a director of Plus Therapeutics (PSTV), received three derivative awards on May 14, 2026 totaling 8,972 restricted stock units (RSUs): two grants of 3,686 RSUs and one grant of 1,600 RSUs. Each grant shows $0 paid (typical for RSU awards), so no cash purchase or sale occurred. These are awards (compensation), not open-market purchases or sales.

Key Details

Transaction date: 2026-05-14; Form 4 filed: 2026-05-18 (filed four days after the transaction; Form 4s are generally required within two business days, so this appears to be later than the usual reporting window).
Grants: 3,686 RSUs + 3,686 RSUs + 1,600 RSUs = 8,972 RSUs; reported acquisition price $0 (derivative award).
Vesting (per footnote F1): RSUs vest ratably over four quarters in substantially equal 1/4 increments, with the first 1/4 vesting on July 1, 2026 and the remainder vesting quarterly thereafter.
Shares owned after the transaction: Not specified in the filing.
Other footnotes in the filing (F2, F3) describe option vesting schedules but are not the awards reported in these specific grant lines.

Context

These were compensation awards (RSUs), not market purchases or sales; such awards are routine for executives/directors and do not directly indicate immediate buying or selling sentiment.
Because these are derivative awards, shares will only be received as the RSUs vest per the stated schedule.

Form 4

Period: 2026-05-14

Director

Transactions

Award
Restricted Stock Units
[F1]
2026-05-14+3,686→ 3,686 total
Exercise: $0.00→ Common Stock (3,686 underlying)
Award
Stock Option (Right to Buy)
[F2]
2026-05-14+3,686→ 3,686 total
Exercise: $5.76Exp: 2036-05-14→ Common Stock (3,686 underlying)
Award
Stock Option (Right to Buy)
[F3]
2026-05-14+1,600→ 1,600 total
Exercise: $5.76Exp: 2036-05-14→ Common Stock (1,600 underlying)

Footnotes (3)

[F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments, commencing with 1/4th vesting on July 1, 2026 and the remainder vesting quarterly thereafter.
[F2]The options vest monthly over 12 months from the grant date in substantially equal monthly increments, provided that the options vest in full on the Issuer's 2027 Annual Stockholder Meeting, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting.
[F3]The options vest monthly over 24 months from the grant date in substantially equaly monthly increments.

Signature

Andrew Sims, as attorney-in-fact|2026-05-18

1 file